Aytu biopharma announces submission of cotempla xr-odt(r) manufacturing site transfer prior approval supplement

Company expects a six-month review of the prior approval supplement submission by the u.s. food & drug administration which, if approved, enables the transfer of cotempla production to contract manufacturer upon completion of manufacturing transfer of adzenys xr-odt and cotempla xr-odt, company expects to improve adhd product margins by an estimated fifteen percent englewood, co / accesswire / july 10, 2023 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on developing and commercializing novel therapeutics, has submitted the cotempla xr-odt® ("cotempla") prior approval supplement (pas) to the u.s. food & drug administration (fda). if approved, the pas would enable aytu to transfer the production of cotempla to the company's third-party manufacturer.
AYTU Ratings Summary
AYTU Quant Ranking